secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001802768-24-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q4 Portfolio Receipts $736M (-31% YoY); FY23 $3,049M (+9%); FY24 guide $2.6-2.7B
--------------------------------------------------------------------------------

- Portfolio Receipts Q4 $736M (down 31% YoY due to prior-year accelerated Biohaven payments); FY23 $3,049M (+9%).
- FY24 guidance: Portfolio Receipts $2.6B-$2.7B, implying royalty receipts growth of 5-9% YoY.
- Announced new transactions up to $4.0B in 2023; capital deployed $2.2B in 2023.
- Repurchased ~10M shares for $305M in 2023 under $1B buyback program.
- Positive clinical updates: aficamten Ph3 success, BMS to acquire Karuna, Novartis to acquire MorphoSys.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/0001802768-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/rprx-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001802768-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer